Vimarsana
Biggest News Aggregation in the World

Page 2 - Dose Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dose Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dose Data Today - Breaking & Trending Today

MSNBC Hallie Jackson Reports February 11, 2022 20:25:00 - Vimarsana News

MSNBC Hallie Jackson Reports February 11, 2022 20:25:00

In reviewing that data, the fda made a determination that they would rather see true efficacy numbers an effectiveness. they may actually not just need to rely on this but look at actual cases to determine whether or not they want to move forward with an authorization or approve this request for expansion of their data. >> so is it as simple they know two doses are not cutting it and they need to make sure that they can test that three dose dozen? >> they have a lot of pushback for even approval two doses of a vaccine that in and of themselves was not adequate in terms of -- or the prediction ...

DGAP-News: Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection - Vimarsana News

DGAP-News: Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection

(0) DGAP-News: Immunic, Inc. / Key word(s): Study results Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection 15.04.2021 / 12:30 The issuer is solely responsible for the content of this announcement. Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection - Preplanned Interim Analysis of 12-Week MRI Data from 10 mg IMU-838 Dose and Placebo, in Comb...